Skip to main content
. 2023 Apr 28;12(9):3179. doi: 10.3390/jcm12093179

Figure 2.

Figure 2

Number and prevalence of patients with G6PD deficiency among geographic regions. (a) The number of patients tested for erythrocyte enzyme activity test, available from the public database by HIRA; (b) the number of patients managed for G6PD deficiency in 2021 (available from the public database by HIRA); (c) the presumptive prevalence of G6PD deficiency (%) based on the number of G6PD deficiency patients/the number of patients tested for erythrocyte enzyme activity test × 100; (d) the number of patients tested for G6PD activity in the study population; (e) the prevalence of patients with G6PD deficiency (<30% of adjusted male median) in the study population; (f) the prevalence of patients with intermediate G6PD activity in female subjects (30–80% of adjusted male median) in the study population.